Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 5, 2011, Pages 825-833

  Tavira, Beatriz ^a   Garciá, Eliecer Coto ^a,b,c   Díaz Corte, Carmen ^c   Ortega, Francisco ^a   Arias, Manuel ^b,d   Torres, Armando ^b,e   Díaz, Juan M ^f   Selgas, Rafael ^b,g   López Larrea, Carlos ^a,b   Campistol, Josep M ^b,h   Alvarezca, Victoria ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Fundacion Renal Inigo Alvarez de Toledo   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^f FUNDACIÓ PUIGVERT   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

cytochrome P450; pharmacogenetics; pharmacokinetics; renal transplantation; tacrolimus

Indexed keywords

ACETYL TRANSFERASE 2; ACYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; CYTOCHROME P450 4A; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; THIOPURINE TRANSFERASE; TRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHEMOLUMINESCENCE; COMPARATIVE STUDY; DNA POLYMORPHISM; DNA REPLICATION; DRUG DETERMINATION; DRUG MEGADOSE; GENE INTERACTION; GENOTYPE; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; DNA; ENDPOINT DETERMINATION; ENZYMES; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, GENETIC; REPRODUCIBILITY OF RESULTS; TACROLIMUS; YOUNG ADULT;

EID: 79954511956     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.143     Document Type: Article

References (33)

1. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schrei-ber SL. Calcineurin is a common target of cyclophilin-cyclo-sporin A and FKBP-FK506 complexes. Cell 1991;66:807-15. (Pubitemid 121001714)
2. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000;80:1483-521.
3. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-75. (Pubitemid 27526900)
4. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005;67:2440-7. (Pubitemid 41623408)
5. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374-84.
6. Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 2000;32:1689-92.
7. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68. (Pubitemid 32324448)
8. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005;51: 1374-81. (Pubitemid 41060869)
9. Iwasaki K, Shiraga T, Nagase K, Hirano K, Nozaki K, Noda K Pharmacokinetic study of FK 506 in the rat. Transplant Proc 1991;23:2757-9.
10. Vincent SH, Karanam BV, Painter SK, Chiu SH. In vitro metab-olism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992;294:454-60.
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91. (Pubitemid 32268418)
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9. (Pubitemid 33151512)
13. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic poly-morphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003;76:1233-5. (Pubitemid 37339651)
14. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipi-ents. Transplantation 2004;78:1182-7. (Pubitemid 39426437)
15. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymor-phisms on the pharmacokinetics of tacrolimus in renal trans-plant recipients. Transplant Proc 2005;37:1730-2. (Pubitemid 40790812)
16. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Vik-licky O. Haplotypic structure ofABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recip-ients. Transplantation 2008;86:1206-13.
17. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacro-limus concentration in the early stage after renal transplanta-tion. Clin Transplant 2005;19:638-43. (Pubitemid 41341696)
18. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 2006;6:2706-13. (Pubitemid 44571691)
19. Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus phar-macokinetics in renal transplant recipients. Pharmacogenet Genomics 2006;16:659-65. (Pubitemid 44223077)
20. Mourad M, Wallemacq P, De Meyer M, Brandt D, Van Kerk-hove V Malaise J, et al. The influence of genetic polymor-phisms of cytochrome P450 3A5 and ABCB1 on starting dose-and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 2006;44:1192-8. (Pubitemid 44580800)
21. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y CYP3A5 and CYP3A4 but not MDR1 sin-gle-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711-25. (Pubitemid 350114816)
22. Wallemacq P, Goffinet JS, O'Morchoe S, Rosiere T, Maine GT, Labalette M, et al. Multi-site analytical evaluation of the Abbott ARCHITECTtacrolimus assay TherDrug Monit 2009;31:198-204.
23. Cuyas E, Olano-Martin E, Khymenets O, Hernandez L, Jofre-Monseny L, Grandoso L, et al. Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 2010;11:257-66.
24. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003;14:1889-96. (Pubitemid 36750485)
25. Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, et al. The effect of MDR1 (ABCB1) polymorphism on the phar-macokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 2006;38:1290-2.
26. Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chi-nese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 2006;38:2850-2. (Pubitemid 44737980)
27. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacoki-netics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54. (Pubitemid 37083100)
28. Amann S, Parker TS, Levine DM. Evaluation of 2 immuno-assays for monitoring low blood levels of tacrolimus. Ther Drug Monit 2009;31:273-6.
29. De BK, Jimenez E, De S, Sawyer JC, McMillin GA. Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx meth-ods. Clin Chim Acta 2009;410:25-30.
30. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun 1999;259:201-5. (Pubitemid 29264018)
31. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Reb-beck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003;42:299-305. (Pubitemid 38054375)
32. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010;87: 721-6.
33. Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Mar-coux F, Urien S, et al. Population pharmacokinetics and Bayes-ian estimation of tacrolimus exposure in renal transplant recip-ients on a new once-daily formulation. Clin Pharmacokinet 2010;49:683-92.